Investment holding platform HKU New Drugs (HKND) begins M&A expansion as it bets on the biotech sector

As the third quarter of 2021 draws to a close, the overall performance of the global capital markets in the first half of the year has become more polarised: US stocks have been the strongest and are still in an upward cycle, while A-shares are now generally in a correction mode after the ups and downs of the first quarter, and Hong Kong stocks have been pulling back after peaking in the first two months, especially since June when they have been in a downward spiral, causing concern to investors.

However, the market cannot be separated from the "cycle", and many people believe that after this round of decline, the negative factors in Hong Kong stocks will be gradually digested. The positive factors will gradually rise, which reminds people of the rise of the biotechnology sector in Hong Kong stocks in 2020 to "save the market. This is reminiscent of the 2020 Hong Kong stock market when the biotechnology sector rose to "save the market".

Biotech industry performs 'bailout' feat in 2020

As a new pneumonia epidemic spread around the world in early 2020, the major capital markets experienced turbulent performance, except for the biotechnology and health sector, which was a "disease saver", making the large pharmaceutical sector a favourite among global capitalists last year.

In particular, the biopharmaceutical sector has become a significant force in the Hong Kong market, with the unprofitable biotech companies listed in 18A showing the vitality and unlimited potential of the Hong Kong capital market and boosting investors' confidence. The table below shows the ten best performing unprofitable biotech companies in the Hong Kong stock market for the year 2020, which is a true reflection of the popularity of biotech companies in the capital market during the year.

The time comes to 2021, and the global biotechnology industry circuit is still quite lively, with a long queue of biotech companies applying for listing through 18A in Hong Kong stocks, hoping to break new ground in the big stage of the Hong Kong capital market in the future.

Against this backdrop, global capital has been scrambling to develop the biotechnology industry in a bid to gain an advantageous competitive position in the fierce competition. In the midst of this trend,HKND, which is determined to bet on the biotechnology sector, has already started the road of M&A expansion with investment holding as the primary means.

HKND explores global M&A opportunities as it bets on biotechnology

As a development platform company with investment holding as its primary business, HKND has set its eyes on the global cutting-edge biotechnology field, indeed betting its treasure on the professional track of biotechnology. It is understood that HKND is mainly engaged in professional mergers and acquisitions and deep integration of high-quality assets in the global high-tech biological field through strategic investment, participation in operations and holding at the helm of the company in a multi-level manner.

The company is based on life science and technology research and development, focusing on cutting-edge innovative drug development powered by AI artificial intelligence advanced data science, and is committed to building a global cutting-edge biotechnology industry eco-development platform through investment holding and M&A integration.Headquartered in Singapore and Hong Kong, HKND aspires to be globally based, with a global perspective to explore the most cutting-edge and value-potential biotech M&A opportunities globally.

With its roots in the biotechnology industry, HKND has clearly insisted on leading innovation through technology, pursuing, exploring and developing core technologies in the biomedical field, and aiming to solve the most challenging health problems through the world's leading technologies.

It is reported that technology has always been the core driving force behind the high-quality development of HKU Pharma, and it has invested a large amount of money in the field of technology research and development to support the company's high-tech research and development business. In addition, the company has recruited the world's best scientific and technological talents, with more than 80% of its core team members being researchers, which has contributed to HKU Pharma's top-notch research strength and built up a solid technological barrier of innovation expertise.

Innovative management system driven, unique business model runs efficiently

From the operation of the business model, HKND is standing on a global perspective, discovering, linking, aggregating and attracting leading biotechnology companies from all over the world, and then establishing a whole industry chain ecosystem in the high-tech biotechnology field by means of strategic investment, participation in operation and management, holding the helm, etc., through professional mergers and acquisitions and deep integration, and at the same time giving its ecological enterprises a full range of capital, resources, talents and other The company also provides its eco-enterprises with capital, resources and talents to form industrial synergies and linkages, and then leads the vertical exploration and horizontal expansion of the industrial eco-aggregation to achieve three-dimensional leapfrog development ultimately.

A mature innovation management system is the basis for the efficient operation of the HKND business model. The company has built an innovation management system internally - talented managers develop excellent development plans, and the implementation process uses first-class tools to build processes that can be continuously optimised, thus improving the efficiency of the execution of each step, which in turn generates excellent development benefits; excellent performance and high expectations will in turn attract more highly qualified people The cycle continues.

In all aspects of the internal innovation management system, HKND focuses on nurturing and retaining top talent. It has formed a diverse management team to provide a platform for employees to fully develop their individual and team values and an open positive and innovative atmosphere and soil.

The company also strives for excellence in execution by re-engineering the way it works, enhancing the flexibility of its teams, improving the company's productivity and freeing up resources, etc. to help the company continue to invest in innovation and achieve better returns. At the same time, HKND is also pushing ahead with its significant data usage and digital management, hoping to drive a digital revolution within the company, using digital technology, advanced analytics and artificial intelligence to drive innovation and improve overall performance.

Circular operation of business model opens the way for expansion of HKU New Drugs (HKND)

With solid capital strength, we make controlling investments and acquisitions of high-quality project assets in the field of cutting-edge biotechnology, and then introduce the powerful active post-investment management of our own innovation management system, HKND completes the deep integration of the ecological industry chain, helps the ecological enterprises achieve efficient synergy with each other, and maximises and realises the value benefits of the industry chain through the competitive advantages of high-tech innovation and research, thus enabling us to This enables us to generate more cash flow and ultimately achieve repeated accumulation of capital.

Driven by the innovation management system, HKND has formed a closed-loop business model of "capital energy - M&A holding - integration and synergy - innovation and R&D - value benefits", and through the cyclical operation of this model, it has started a positive development journey of continuous expansion.

It is reported that the segments that HKND focuses on cover cutting-edge new drug creation, digital life, innovative precision medical devices, IVD and precision medicine and other new medical technologies. The scale of its eco-enterprises is growing, and it even holds a global multi-omics digital life ecosystem, cutting-edge technologies in the field of precision medicine in infection medicine, the most cutting-edge lysing bacterial immunotherapy technology in the field of tumour immunotherapy, and AI+ new drug development and other essential core technologies in the global biomedical field, and has now demonstrated outstanding quality in the global high-tech innovation and development field.

As the company continues to expand and grow, there will be a place for HKND at the forefront of the biotechnology industry, and we look forward to more stories to come.